CIM Investment Management’s TG Therapeutics TGTX Stock Holding History

CIM Investment Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$349K	Buy	+6,344	New	+$260K	0.08%	190
2025 Q4	–	Sell	-5,915	Closed	-$214K	–	252
2025 Q3	$214K	Sell	5,915 -105	-2%	-$3.46K	0.06%	222
2025 Q2	$217K	Sell	6,020 -100	-2%	-$3.72K	0.04%	234
2025 Q1	$241K	Buy	+6,120	New	+$206K	0.06%	201
2023 Q2	–	Sell	-15,521	Closed	-$233K	–	293
2023 Q1	$233K	Buy	15,521 +535	+4%	+$8.13K	0.09%	224
2022 Q4	$177K	Hold	14,986	–	–	0.07%	229
2022 Q3	$89K	Hold	14,986	–	–	0.04%	214
2022 Q2	$64K	Hold	14,986	–	–	0.03%	228
2022 Q1	$143K	Buy	+14,986	New	+$173K	0.05%	242
2021 Q4	–	Sell	-6,214	Closed	-$207K	–	315
2021 Q3	$207K	Hold	6,214	–	–	0.07%	284
2021 Q2	$241K	Buy	+6,214	New	+$244K	0.07%	254

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

CIM Investment Management's TGTX Position: Q2 2026 in Review

CIM Investment Management opened a new position in TG Therapeutics (TGTX) in Q2 2026: 6,344 shares worth $349K. The stake represents 0.08% of the portfolio and ranks #190 among its holdings. This is a return to the name: CIM Investment Management previously reported a position in TGTX as recently as Q3 2025.

CIM Investment Management first reported a position in TGTX in Q2 2021 and has held it in 11 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

CIM Investment Management held 6,344 shares of TG Therapeutics worth $349K as of Q2 2026.
TG Therapeutics was a new CIM Investment Management position in Q2 2026.
TG Therapeutics made up 0.08% of CIM Investment Management's portfolio in Q2 2026, its #190 holding.
CIM Investment Management first reported a position in TG Therapeutics in Q2 2021 and has held it in 11 quarters since.
431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on CIM Investment Management's 13F filing for Q2 2026, filed 29 Sep 2026.